| A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (NCT04919512) | Janssen Research & Development, LLC | 2022-07-07 |
| A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours (NCT05397171) | AstraZeneca | 2022-06-07 |
| Urinary Continence of Female POPRC and OIN (NCT05325216) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2022-04-01 |
| Lymphedema After Urologic Surgery (NCT05264337) | Vastra Gotaland Region | 2022-03-14 |
| Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer (NCT06892860) | Queen Mary University of London | 2021-12-16 |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) (NCT05014139) | Astellas Pharma Global Development, Inc. | 2021-12-07 |
| Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients (NCT05068180) | RenJi Hospital | 2021-10-05 |
| Effect of Pelvic Radiotherapy on the Intestinal Microbiome and Metabolome (NCT04995809) | The Christie NHS Foundation Trust | 2021-07-05 |
| Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment (NCT04706598) | Fudan University | 2021-06-09 |
| Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) (NCT04922047) | RenJi Hospital | 2021-06-01 |
| Narrow-band Imaging Diagnostic Classification System for Bladder Tumors (NCT05611762) | Qilu Hospital of Shandong University (Qingdao) | 2021-01-01 |
| A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (NCT04640623) | Janssen Research & Development, LLC | 2020-12-18 |
| A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (NCT04658862) | Janssen Research & Development, LLC | 2020-12-07 |
| AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer (NCT04430036) | The University of Texas Health Science Center at San Antonio | 2020-10-14 |
| Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC (NCT04819399) | Lindis Biotech GmbH | 2020-07-07 |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors (NCT04389632) | Seagen, a wholly owned subsidiary of Pfizer | 2020-06-08 |
| Prospective Sample Collection for Cancer of Bladder (NCT03973671) | Universitaire Ziekenhuizen KU Leuven | 2020-05-29 |
| Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) (NCT04241185) | Merck Sharp & Dohme LLC | 2020-05-19 |
| A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) (NCT04172675) | Janssen Research & Development, LLC | 2020-02-28 |
| Effect of Head Elevation on LMA Insertion (NCT04229862) | Asan Medical Center | 2020-02-14 |
| A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102 (NCT04109092) | Eisai Inc. | 2020-02-13 |
| A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (NCT04149574) | Bristol-Myers Squibb | 2020-01-15 |
| BladMetrix Urine Test for Monitoring Recurrence in Non-Muscle Invasive Bladder Cancer (NCT07511517) | Oslo University Hospital | 2019-10-03 |
| Study Comparing Open Radical Cystectomy With Robot-assisted Cystectomy in Patients With Bladder Cancer (NCT03977831) | Rigshospitalet, Denmark | 2019-06-06 |
| A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer (NCT03661320) | Bristol-Myers Squibb | 2018-11-06 |
| A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder (NCT03519256) | Bristol-Myers Squibb | 2018-08-02 |
| Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) (NCT03258593) | National Cancer Institute (NCI) | 2018-06-07 |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer (NCT03081858) | Lipac Oncology LLC | 2018-05-17 |
| Effect of PEEP on Arterial Oxygen Partial Pressure in Elderly Patients With Lithotomy Position Using LMA Supreme™ (NCT03390127) | Asan Medical Center | 2018-01-05 |
| A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy (NCT03404791) | Janssen Research & Development, LLC | 2017-11-20 |
| TURBt With Adjuvant Cryoablation to Treat Bladder Cancer (NCT02760953) | Huashan Hospital | 2017-10-19 |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (NCT03288545) | Astellas Pharma Global Development, Inc. | 2017-10-11 |
| A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (NCT03219333) | Astellas Pharma Inc | 2017-10-08 |
| Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (NCT02788201) | National Cancer Institute (NCI) | 2017-03-27 |
| LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer (NCT02612194) | Wake Forest University Health Sciences | 2016-09-27 |
| uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer (NCT02805608) | Rigshospitalet, Denmark | 2016-09-01 |
| The Bladder Instillation Comparison Study (NCT02695771) | Corewell Health West | 2016-04-19 |
| Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma (NCT02619253) | Nabil Adra | 2016-02-23 |
| Ultrasound-Guided ONB for Transurethral Procedures - Interadductor Approach (NCT02696733) | Medical University of Warsaw | 2016-02-01 |
| CIK in Treating Patients With Bladder Cancer (NCT02489890) | The First People's Hospital of Changzhou | 2016-02-01 |
| Impacts of Different Pressure Pneumoperitoneum on Myocardial and Pulmonary Injuries After Robot-assisted Surgery (NCT02600481) | Huadong Hospital | 2016-01-01 |
| Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer (NCT02560038) | The University of Texas Health Science Center, Houston | 2015-10-01 |
| Postoperative Quality of Recovery After Transurethral Resection of the Bladder (NCT02534623) | General Hospital Zadar | 2015-09-01 |
| Molecular Biosensors for Detection of Bladder Cancer (NCT02957370) | University of California, Irvine | 2015-06-11 |
| Cystoscopic Imaging Collection and Enhancement pROject (NCT02427321) | Biosignatures Limited | 2015-05-01 |
| Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer (NCT02381912) | Herlev Hospital | 2015-03-01 |
| Peri-operative Aspirin Continuation Versus Discontinuation (NCT02350543) | Rabin Medical Center | 2015-02-01 |
| Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms (NCT02430623) | Fuda Cancer Hospital, Guangzhou | 2015-01-01 |
| Propofol and Sevoflurane for Catheter-Related Bladder Discomfort (NCT02252445) | Seoul National University Hospital | 2014-11-01 |
| Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level (NCT02778243) | Hopital Foch | 2014-09-01 |
| Sevoflurane Versus Desflurane for Catheter-related Bladder Discomfort (NCT02096224) | Seoul National University Hospital | 2014-05-01 |
| Trimodality Treatment in Bladder Cancer (NCT06395701) | Consorci Sanitari de Terrassa | 2014-04-01 |
| Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study (NCT01868087) | Jill Hamilton-Reeves, PhD RD LD | 2013-07-01 |
| Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients (NCT02891460) | UroGen Pharma Ltd. | 2013-01-01 |
| Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer (NCT01631552) | Gilead Sciences | 2012-12-17 |
| Cabozantinib for Advanced Urothelial Cancer (NCT01688999) | National Cancer Institute (NCI) | 2012-09-11 |
| Radical Cystectomy, Nutrition and Convalescence (NCT02238886) | Rigshospitalet, Denmark | 2012-05-01 |
| A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors (NCT01478685) | Celgene | 2011-11-29 |
| Imaging Study for FdCyd and THU Cancer Treatment (NCT01479348) | National Cancer Institute (NCI) | 2011-11-01 |
| Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy (NCT01435356) | European Association of Urology Research Foundation | 2011-08-01 |
| Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma (NCT01342172) | Icahn School of Medicine at Mount Sinai | 2011-03-01 |
| Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer (NCT01261299) | University of California, Davis | 2010-12-01 |
| A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) (NCT00978250) | National Cancer Institute (NCI) | 2009-08-20 |
| Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer (NCT00818350) | Campania Younger Oncologists Association | 2009-01-01 |
| Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer (NCT00625664) | Sanofi | 2008-02-01 |
| Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment (NCT00710970) | Seth Lerner | 2007-01-01 |
| Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer (NCT00384891) | Medical Enterprises Europe B.V. | 2002-02-01 |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I (NCT02254915) | Medical Enterprises Europe B.V. | |
| Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors (NCT07675057) | Eli Lilly and Company | |